Pipeline

Name of The Drug
Research Type/Indication
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Dorzagliatin
Drug naïve T2D
Hepatic impaired T2D
Renal impaired T2D
Dorzagliatin+Metformin
Metformin Tolerance T2D
Dorzagliatin+DPP-4
Obesity T2D
Dorzagliatin+SGLT-2
Metabolic syndrome
Dorzagliatin+GLP-1
GLP-1 tolerated T2D
Dorzagliatin+Insulin
Basal insulin tolerated T2D
Drug naïve severe T2D
mGluR5 NAM
PD-LID
Dorzagliatin
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Drug naïve T2D
Hepatic impaired T2D
Renal impaired T2D
Dorzagliatin+Metformin
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Metformin Tolerance T2D
Dorzagliatin+DPP-4
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Obesity T2D
Dorzagliatin+SGLT-2
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Metabolic syndrome
Dorzagliatin+GLP-1
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
GLP-1 tolerated T2D
Dorzagliatin+Insulin
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Basal insulin tolerated T2D
Drug naïve severe T2D
mGluR5 NAM
Preclinical
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
PD-LID
Focus Us
Copyright © 2020  Hua Medicine (Shanghai) Co., Ltd. 沪ICP备14036654号    beiantubiao.png 沪公网安备 31011502013809号
Search